Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 171544-35-7
Drug Levels and Effects
Summary of Use during Lactation
Ferumoxsil is not approved for marketing in the United States by the U.S. Food and Drug Administration. No information is available on the clinical use of ferumoxsil during breastfeeding. If ferumoxsil is required by the mother, it is not a reason to discontinue breastfeeding.[1] However, since there is no published experience with ferumoxsil during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Cova MA, Stacul F, Quaranta R et al. Radiological contrast media in the breastfeeding woman: a position paper of the Italian Society of Radiology (SIRM), the Italian Society of Paediatrics (SIP), the Italian Society of Neonatology (SIN) and the Task Force on Breastfeeding, Ministry of Health, Italy. Eur Radiol. 2014;24:2012-22. [PubMed: 24838733]
Substance Identification
Substance Name
Ferumoxsil
CAS Registry Number
171544-35-7
Drug Class
- Breast Feeding
- Contrast Media
- Diagnostic Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubMedLinks to PubMed
- Review Ferumoxides.[Drugs and Lactation Database (...]Review Ferumoxides.. Drugs and Lactation Database (LactMed®). 2006
- Review Almotriptan.[Drugs and Lactation Database (...]Review Almotriptan.. Drugs and Lactation Database (LactMed®). 2006
- Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil.[Magn Reson Imaging. 1995]Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil.Jung CW. Magn Reson Imaging. 1995; 13(5):675-91.
- Review Ferumoxsil.[Molecular Imaging and Contrast...]Review Ferumoxsil.Leung K. Molecular Imaging and Contrast Agent Database (MICAD). 2004
- Review Linezolid.[Drugs and Lactation Database (...]Review Linezolid.. Drugs and Lactation Database (LactMed®). 2006
- Ferumoxsil - Drugs and Lactation Database (LactMed®)Ferumoxsil - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...